Search tips
Search criteria 


Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
J Exp Med. 1976 October 1; 144(4): 970–984.
PMCID: PMC2190433

Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway


In earlier studies we found that human serum, but not serum from multiple other species, inactivated and lysed oncornaviruses from a number of diverse sources in the apparent absence of antibody. A detailed analysis of the role of the human complement (C) system in mediating this lytic process indicates that human C1q interacts directly, in the absence of immunoglobulin, with oncornaviruses. Binding of C1 via C1q in this manner leads to activation of C1r, C1s, and thus of the classical C pathway. Integrity of the classical pathway is an absolute requirement for lysis although activation of the alternative pathway considerably amplifies the amount of lysis obtained, possibly through involvement of the C3b-dependent feedback mechanism. Activation of C is accompanied by deposition of C components on the viral surface and lysis on completion of the C reaction sequence. Thus in this system, the C1q subunit of C1 subserves a specific recognition function normally associated with antibody. This ability of human serum to inactivate oncornaviruses may represent a natural defense mechanism operative in vivo which deters expression of intact oncornaviruses in human malignancies.

Full Text

The Full Text of this article is available as a PDF (1.2M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Huebner RJ, Todaro GJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci U S A. 1969 Nov;64(3):1087–1094. [PubMed]
  • Baxt WG, Spiegelman S. Nuclear DNA sequences present in human leukemic cells and absent in normal leukocytes. Proc Natl Acad Sci U S A. 1972 Dec;69(12):3737–3741. [PubMed]
  • Gallo RC, Miller NR, Saxinger WC, Gillespie D. Primate RNA tumor virus-like DNA synthesized endogenously by RNA-dependent DNA polymerase in virus-like particles from fresh human acute leukemic blood cells. Proc Natl Acad Sci U S A. 1973 Nov;70(11):3219–3224. [PubMed]
  • Baxt W, Hehlmann R, Spiegelman S. Human leukaemic cells contain reverse transcriptase associated with a high molecular weight virus-related RNA. Nat New Biol. 1972 Nov 15;240(98):72–75. [PubMed]
  • Sarngadharan MG, Sarin PS, Reitz MS, Gallo RC. Reverse transcriptase activity of human acute leukaemic cells: purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product. Nat New Biol. 1972 Nov 15;240(98):67–72. [PubMed]
  • Todaro GJ, Gallo RC. Immunological relationship of DNA polymerase from human acute leukaemia cells and primate and mouse leukaemia virus reverse transcriptase. Nature. 1973 Jul 27;244(5413):206–209. [PubMed]
  • Strand M, August JT. Type-C RNA virus gene expression in human tissue. J Virol. 1974 Dec;14(6):1584–1596. [PMC free article] [PubMed]
  • Sherr CJ, Todaro GJ. Primate type C virus p30 antigen in cells from humans with acute leukemia. Science. 1975 Mar 7;187(4179):855–857. [PubMed]
  • Zurcher C, Brinkhof J, Bentvelzen P, De Man JC. C-type virus antigens detected by immunofluorescence in human bone tumour cultures. Nature. 1975 Apr 3;254(5499):457–459. [PubMed]
  • Yeh J, Ahmed M, Mayyasi SA, Alessi AA. Detection of an antigen related to Mason-Pfizer virus in malignant human breast tumors. Science. 1975 Nov 7;190(4214):583–584. [PubMed]
  • Hirshaut Y, Reagan RL, Perry S, De Vita V, Jr, Barile MF. The search for a viral agent in Hodgkin's disease. Cancer. 1974 Oct;34(4):1080–1089. [PubMed]
  • Panem S, Prochownik EV, Reale FR, Kirsten WH. Isolation of type C virions from a normal human fibroblast strain. Science. 1975 Jul 25;189(4199):297–299. [PubMed]
  • Kalter SS, Helmke RJ, Heberling RL, Panigel M, Fowler AK, Strickland JE, Hellman A. Brief communication: C-type particles in normal human placentas. J Natl Cancer Inst. 1973 Apr;50(4):1081–1084. [PubMed]
  • Teich NM, Weiss RA, Salahuddin SZ, Gallagher RE, Gillespie DH, Gallo RC. Infective transmission and characterisation of a C-type virus released by cultured human myeloid leukaemia cells. Nature. 1975 Aug 14;256(5518):551–555. [PubMed]
  • Aaronson SA, Todaro GJ. Transformation and virus growth by murine sarcoma viruses in human cells. Nature. 1970 Jan 31;225(5231):458–459. [PubMed]
  • Sarma PS, Sharar A, Walters V, Gardner M. A survey of cats and humans for prevalence of feline leukemia-sarcoma virus neutralizing serum antibodies. Proc Soc Exp Biol Med. 1974 Feb;145(2):560–564. [PubMed]
  • Charman HP, Kim N, White M, Gilden RV. Failure to detect, in human sera, antibodies cross-reactive with group-specific antigens of murine leukemia virus. J Natl Cancer Inst. 1974 May;52(5):1409–1413. [PubMed]
  • Hersh EM, Hanna MG, Jr, Gutterman JU, Mavligit G, Yurconic M, Jr, Gschwind CR. Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity. J Natl Cancer Inst. 1974 Aug;53(2):327–333. [PubMed]
  • Kim BS. Presence of antibody to a primate RNA virus in human plasma. Nature. 1975 Oct 16;257(5527):614–616. [PubMed]
  • Essex M. Horizontally and vertically transmitted oncornaviruses of cats. Adv Cancer Res. 1975;21:175–248. [PubMed]
  • Ihle JN, Hanna MG, Jr, Roberson LE, Kenney FT. Autogenous immunity to endogenous RNA tumor virus. Identification of antibody reactivity to select viral antigens. J Exp Med. 1974 Jun 1;139(6):1568–1581. [PMC free article] [PubMed]
  • Gallagher RE, Gallo RC. Type C RNA tumor virus isolated from cultured human acute myelogenous leukemia cells. Science. 1975 Jan 31;187(4174):350–353. [PubMed]
  • Nooter K, Aarssen AM, Bentvelzen P, De Groot FG, Van Pelt FG. Isolation of infectious C-type oncornavirus from human leukaemic bone marrow cells. Nature. 1975 Aug 14;256(5518):595–597. [PubMed]
  • Mak TW, Kurtz S, Manaster J, Housman D. Viral-related information in oncornavirus-lik particles isolated from cultures of marrow cells from leukemic patients in relapse and remission. Proc Natl Acad Sci U S A. 1975 Feb;72(2):623–627. [PubMed]
  • McAllister RM. Viruses in human carcinogenesis. Prog Med Virol. 1973;16:48–85. [PubMed]
  • Welsh RM, Jr, Cooper NR, Jensen FC, Oldstone MB. Human serum lyses RNA tumour viruses. Nature. 1975 Oct 16;257(5527):612–614. [PubMed]
  • Yonemasu K, Stroud RM. Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies. J Immunol. 1971 Feb;106(2):304–313. [PubMed]
  • Ziccardi RJ, Cooper NR. Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol. 1976 Feb;116(2):496–503. [PubMed]
  • Valet G, Cooper NR. Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol. 1974 Jan;112(1):339–350. [PubMed]
  • Cooper NR, Polley MJ, Müller-Eberhard HJ. The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry. 1970 Apr;7(4):341–356. [PubMed]
  • Schreiber RD, Müller-Eberhard HJ. Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med. 1974 Nov 1;140(5):1324–1335. [PMC free article] [PubMed]
  • Götze O, Müller-Eberhard HJ. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed]
  • Cooper NR, Müller-Eberhard HJ. A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry. 1968 Mar;5(2):155–169. [PubMed]
  • Cooper NR, ten Bensel R, Kohler PF. Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol. 1968 Dec;101(6):1176–1182. [PubMed]
  • Sobel AT, Bokisch VA, Müller-Eberhard HJ. C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med. 1975 Jul 1;142(1):139–150. [PMC free article] [PubMed]
  • McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. [PubMed]
  • Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed]
  • Cooper NR, Müller-Eberhard HJ. The reaction mechanism of human C5 in immune hemolysis. J Exp Med. 1970 Oct 1;132(4):775–793. [PMC free article] [PubMed]
  • Kolb WP, Müller-Eberhard HJ. Mode of action of human C9: adsorption of multiple C9 molecules to cell-bound C8. J Immunol. 1974 Aug;113(2):479–488. [PubMed]
  • Pinckard RN, Olson MS, Kelley RE, DeHeer DH, Palmer JD, O'Rourke RA, Goldfein S. Antibody-independent activation of human C1 after interaction with heart subcellular membranes. J Immunol. 1973 May;110(5):1376–1382. [PubMed]
  • Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol. 1974 Jul;113(1):9–17. [PubMed]
  • Natali PG, Tan EM. Precipitin reactions between polyribonucleotides and heat labile serum factors. J Immunol. 1972 Feb;108(2):318–324. [PubMed]
  • Rent R, Ertel N, Eisenstein R, Gewurz H. Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol. 1975 Jan;114(1 Pt 1):120–124. [PubMed]
  • Okada H, Baba T. Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane. Nature. 1974 Apr 5;248(448):521–522. [PubMed]
  • Theofilopoulos AN, Perrin LH. Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes. J Exp Med. 1976 Feb 1;143(2):271–289. [PMC free article] [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press